4-(S)-amino-6-(2,2-dimethyl-propyl)-3,4-dihydro-2H-quinoline-1-carboxylic acid benzyl ester | 861857-50-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-(S)-amino-6-(2,2-dimethyl-propyl)-3,4-dihydro-2H-quinoline-1-carboxylic acid benzyl ester
• 英文别名: 4-(S)-amino-6-(2,2-dimethyl-propyl)-3,4-dihydro-2H-quinolin-1-carboxylic acid benzyl ester；benzyl (4S)-4-amino-6-(2,2-dimethylpropyl)-3,4-dihydro-2H-quinoline-1-carboxylate
• CAS: 861857-50-3
• 化学式: C₂₂H₂₈N₂O₂
• 分子量: 352.477
• InChiKey: XIRPJWMBYHDZCP-IBGZPJMESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-(S)-azido-6-(2,2-dimethyl-propyl)-3,4-dihydro-2H-quinoline-1-carboxylic acid benzyl ester 在 水 、 三甲基膦 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 以77%的产率得到4-(S)-amino-6-(2,2-dimethyl-propyl)-3,4-dihydro-2H-quinoline-1-carboxylic acid benzyl ester
  参考文献：
  名称：

  [EN] METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS
  [FR] PROCEDES DE TRAITEMENT D'AMYLOIDOSE UTILISANT DES INHIBITEURS DE PROTEASE ASPARTYLE

  摘要：

  这项发明涉及乙酰2-羟基-1,3-二氨基螺环己烷及其衍生物，可用于治疗与淀粉样变性相关的疾病、疾病和症状。淀粉样变性是指与A-beta蛋白异常沉积相关的一系列疾病、疾病和症状。

  公开号：

  WO2005070407A1

文献信息

• [EN] SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS<br/>[FR] UREE ET CARBAMATE SUBSTITUES, PHENACYL-2-HYDROXY-3-DIAMINOALCANE, ET BENZAMIDE-2-HYDROXY-3-DIAMINOALCANE INHIBITEURS D'ASPARTYL-PROTEASE
  申请人：ELAN PHARM INC

  公开号：WO2005087215A1

  公开（公告）日：2005-09-22

  The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating at least one disease, disorder, and condition associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and condition associated with abnormal deposition of A-beta protein.

  这项发明涉及乙酰2-羟基-1,3-二氨基螺环己烷及其衍生物，可用于治疗与淀粉样变性相关的至少一种疾病、紊乱和病况。淀粉样变性指与A-beta蛋白异常沉积相关的一系列疾病、紊乱和病况。
• Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
  申请人：John Varghese

  公开号：US20050239832A1

  公开（公告）日：2005-10-27

  The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

  本发明涉及新型化合物和治疗与淀粉样变性相关的疾病、紊乱和状况的方法。淀粉样变性是指与A-beta蛋白异常沉积相关的一系列疾病、紊乱和状况的集合。
• Substituted hydroxyethylamine aspartyl protease inhibitors
  申请人：John Varghese

  公开号：US20050239790A1

  公开（公告）日：2005-10-27

  The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

  本发明涉及新型化合物以及使用此类化合物治疗至少一种与淀粉样变性相关的疾病、失调或病症的方法。淀粉样变性是指与 A-beta 蛋白异常沉积有关的一系列疾病、失调和病症。
• Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
  申请人：John Varghese

  公开号：US20050261273A1

  公开（公告）日：2005-11-24

  The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating at least one disease, disorder, and condition associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and condition associated with abnormal deposition of A-beta protein.

  本发明涉及乙酰基 2-羟基-1,3-二氨基螺环己烷及其衍生物，可用于治疗至少一种与淀粉样变性相关的疾病、失调和病症。淀粉样变性是指与A-β蛋白异常沉积有关的一系列疾病、失调和状况。
• Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors
  申请人：John Varghese

  公开号：US20060014790A1

  公开（公告）日：2006-01-19

  The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

  本发明涉及乙酰基 2-羟基-1,3-二氨基螺环己烷及其衍生物，可用于治疗与淀粉样变性相关的疾病、失调和病症。淀粉样变性是指与 A-beta 蛋白异常沉积有关的一系列疾病、失调和病症。